Dados retrospectivos indicam que um CMM "de novo", status de pré-menopausa, status para receptor estrogênico (RE) positivo, doença HER2 positiva e menos sítios metastáticos estão significativamente associados à sobrevida em longo prazo (definida como ≥5 anos) ao CMM entre mulheres diagnosticadas com CMM.[178]Klar N, Rosenzweig M, Diergaarde B, et al. Features associated with long-term survival in patients with metastatic breast cancer. Clin Breast Cancer. 2019 Aug;19(4):304-10.
http://www.ncbi.nlm.nih.gov/pubmed/30827763?tool=bestpractice.com
[179]Leone JP, Leone J, Vallejo CT, et al. Factors associated with short- and long-term survival in metastatic HER2+ breast cancer. J Clin Oncol. 2022 40:16_suppl, 1047 [Epub ahead of print].
https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.1047
Uma coorte de pacientes relatou melhora da sobrevida global durante o período do estudo (2010 a 2018), com uma proporção considerável de pacientes vivas a 8 anos.[179]Leone JP, Leone J, Vallejo CT, et al. Factors associated with short- and long-term survival in metastatic HER2+ breast cancer. J Clin Oncol. 2022 40:16_suppl, 1047 [Epub ahead of print].
https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.1047
Um estudo anterior, empregando métodos de cálculo retrospectivo, estimou um aumento na taxa de sobrevida relativa a 5 anos entre mulheres diagnosticadas com CMM "de novo" (a idades de 15-49 anos) de 18% entre 1992-1994 para 36% entre 2005-2012.[180]Mariotto AB, Etzioni R, Hurlbert M, et al. Estimation of the number of women living with metastatic breast cancer in the United States. Cancer Epidemiol Biomarkers Prev. 2017 Jun;26(6):809-15.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5833304
http://www.ncbi.nlm.nih.gov/pubmed/28522448?tool=bestpractice.com
A sobrevida melhorada nestes estudos coincide com avanços terapêuticos significativos para CMM positivo para HER2.
A mediana de sobrevida global das pacientes com CMM é de 2-3 anos.[181]Valachis A, Carlqvist P, Ma Y, et al. Overall survival of patients with metastatic breast cancer in Sweden: a nationwide study. Br J Cancer. 2022 Sep;127(4):720-5.
https://www.nature.com/articles/s41416-022-01845-z
http://www.ncbi.nlm.nih.gov/pubmed/35597870?tool=bestpractice.com
[182]Gomes I, Aguiar P, Miranda A, et al. Overall survival of patients with locoregional and metastatic breast cancer: is the influence of baseline characteristics the same? Anticancer Res. 2019 Sep;39(9):5135-42.
https://ar.iiarjournals.org/content/39/9/5135.long
http://www.ncbi.nlm.nih.gov/pubmed/31519625?tool=bestpractice.com
[183]Zeichner SB, Herna S, Mani A, et al. Survival of patients with de-novo metastatic breast cancer: analysis of data from a large breast cancer-specific private practice, a university-based cancer center and review of the literature. Breast Cancer Res Treat. 2015 Oct;153(3):617-24.
http://www.ncbi.nlm.nih.gov/pubmed/26358708?tool=bestpractice.com
Nos Reino Unido, a sobrevida em cinco anos de mulheres diagnosticadas com câncer de mama em estádio 4 (2013-2017, acompanhadas até 2018) é estimada em 26%.[184]Cancer Research UK. Breast cancer survival by stage at diagnosis. Nov 2019 [internet publication].
https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/breast-cancer/survival#heading-Three
Nos EUA, a taxa de sobrevida relativa em 5 anos para mulheres com CMM "de novo" é de 31% (dados de 2013 a 2019).[19]National Cancer Institute (US). Cancer stat facts: female breast cancer [internet publication].
https://seer.cancer.gov/statfacts/html/breast.html